3PB’s Matthew Wyard discusses UK Market Authorisation for new medicinal products
4th June 2020
3PB’s Public and Regulatory barrister Matthew WyardMatthew WyardCall: 2014 has provided an overview of the MHRA’s Market Authorisation process for bringing new products to market in the UK. Designed for the pharmaceutical industry and those advising them, this article looks at the different types of authorisation available and the process for approving medicines in the UK.
To read the full article please click here.
To discuss this article further, or to instruct Matthew on a matter relating to this article or any other matter, please contact his clerks Chris Mitchell on firstname.lastname@example.org or Tom Cox on email@example.com.